EP0370284A2 - Composition contenant un extrait obtenu par extraction à l'aide d'un solvant organique aqueux et procédé de préparation à cet effet - Google Patents

Composition contenant un extrait obtenu par extraction à l'aide d'un solvant organique aqueux et procédé de préparation à cet effet Download PDF

Info

Publication number
EP0370284A2
EP0370284A2 EP89120283A EP89120283A EP0370284A2 EP 0370284 A2 EP0370284 A2 EP 0370284A2 EP 89120283 A EP89120283 A EP 89120283A EP 89120283 A EP89120283 A EP 89120283A EP 0370284 A2 EP0370284 A2 EP 0370284A2
Authority
EP
European Patent Office
Prior art keywords
water
organic solvent
composition
extract
extraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89120283A
Other languages
German (de)
English (en)
Other versions
EP0370284A3 (en
EP0370284B1 (fr
Inventor
Shimesu Motoyama
Seiichi Umeda
Yukihiro Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Freund Corp
Original Assignee
Freund Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Freund Corp filed Critical Freund Corp
Publication of EP0370284A2 publication Critical patent/EP0370284A2/fr
Publication of EP0370284A3 publication Critical patent/EP0370284A3/en
Application granted granted Critical
Publication of EP0370284B1 publication Critical patent/EP0370284B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • This invention relates to a composition containing an extract obtained by extraction with a water-­containing organic solvent, which has a high bioavailability and can be formulated into various preparations including tablets, granules, powder preparations, drinkable preparations, and syrups, and also to a process for preparing said composition.
  • remedial preparations containing, as active ingredient, an extract obtained from plant tissues such as ginkgo leaves by extraction with a water-containing organic solvent have hitherto been used widely for the purpose of improving metabolism of cerebral circulation.
  • the above extract obtained by extraction with a water-containing organic solvent has such pharmacological actions as relaxation of smooth muscles of blood vessels contracted owing to stress, tension, etc., thereby reducing resistance in peripheral arteries and cerebral circulatory system; and vasodilation and increasing of blood flow velocity, thereby increasing blood flow in the pacillary tissues.
  • Said extract is also known to have a pharmacological action of lowering viscosity of the blood in the arteries and veins, thereby smoothing the blood flow, with the result that disorder in the peripheral blood vessels and cerebral blood vessels is improved.
  • the above-mentioned extract obtained by extraction with a water-containing organic solvent has such property that it is soluble in water-containing organic solvents such as water-containing acetone, water-containing methyl ethyl ketone, water-containing methanol and water-containing ethanol, but practically insoluble in water.
  • water-containing organic solvents such as water-containing acetone, water-containing methyl ethyl ketone, water-containing methanol and water-containing ethanol, but practically insoluble in water.
  • the purpose of this invention is to provide a composition which contains an extract obtained by extraction with a water-containing organic solvent and which has a high bioavailability and can be formulated into various forms of preparations including tablets, granules, powder preparations, drinkable preparations and syrups.
  • Another purpose of this invention is to provide a process for preparing said composition containing an extract obtained by extraction with a water-containing organic solvent.
  • composition of this invention is one whose main components are an extract containing active ingredients almost insoluble in water which is obtained from plant tissues by extraction with a water-containing organic solvent, and a water-soluble high-molecular substance and/or a fatty acid ester of polyglycerol.
  • ginkgo leaves As plant tissues, there are exemplified ginkgo leaves, balloon flower (Platycodon grandiflorum A. DC.), carrots, roots of Scopolia japonica Maximowicz, etc.
  • the above-mentioned extracts obtained from plant tissues mean those which are obtained from said plant tissues by extraction in a conventional manner with a water-containing organic solvent such as water-­ containing methanol, water-containing ethanol, water-­containing acetone, and water-containing methyl ethyl ketone, and from which the water-containing solvent has been distilled off.
  • a water-containing organic solvent such as water-­ containing methanol, water-containing ethanol, water-­containing acetone, and water-containing methyl ethyl ketone
  • water-soluble high-molecular substance there are no particular restrictions provided it is a pharmaceutically acceptable substance, and those desirable include gum arabic, xanthan gum, guar gum, gum extracted from tamarind seeds, and sodium alginate. Of these, gum arabic is especially preferable.
  • fatty acid ester of polyglycerol any such ester may be used. However, it is desirable to use monostearate, monooleate or monolaurate of decaglycerin; monostearate, monooleate or monolaurate of hexaglycerin; and monolaurate of tetraglycerin, provided HLB of the ester is 10 or higher.
  • an extract obtained as above by extraction with a water-­containing organic solvent, and a water-soluble high-­molecular substance and/or a fatty acid ester of polyglycerol are mixed first.
  • the two (or three) components are first dissolved and evenly mixed in a water-containing lower alcohol, and then the solvent (water-containing lower alcohol) is distilled off, followed by drying, there is obtained a composition whose active ingredients have an improved solubility and a very high bioavailability.
  • a water-containing lower alcohol to be used in this process it is desirable to use an aqueous solution of alcohol with 20 - 45 v/v % content of lower alcohol.
  • As lower alcohol there are exemplified methanol, ethanol, isopropanol, etc., of which ethanol is especially preferable.
  • Concrete methods of preparation include the following:
  • the mixture, prepared as above, of an extract obtained by extraction with a water-containing organic solvent, and a water-soluble high-molecular substance and/or a fatty acid ester of polyglycerol is mixed with a publicly-known excipient or excipients, and then a binder is added.
  • the mixture thus prepared is then granulated in a fluidized bed, whereby granules of the composition of this invention are obtained.
  • the granules can also be tableted after adding a suitable lubricant.
  • Either a water-soluble high-molecular substance or a fatty acid ester of polyglycerol may be used, but when both are used, better results are obtained in many cases as compared with the use of only one of the two.
  • the solid preparations, made as above, of the composition of this invention are soluble in water or dispersible in water in fine particles, thereby making it easy to be absorbed into the digestive tract, and as a result, a bioavailability equal to that of conventional alcohol-containing liquid preparations is obtained.
  • binder In addition to excipient, binder, lubricant, and disintegrator, there may be added to the composition of this invention other additives generally accepted for foods and pharmaceuticals. These include sweetener and perfume which are used to improve taste, and surfactant used to stabilize dispersion.
  • the product may also be coated.
  • composition of this invention can also be dissolved or emulsified in water without the use of ethanol or with the use of a very small amount (1%) of ethanol, thereby making it possible to formulate it into liquid preparations having a good absorbency in the digestive tract.
  • sweeteners such as saccharose, glucose, sorbitol, maltitol, stevia, and aspartame
  • preservatives such as sodium benzoate, and p-hydroxy benzoate.
  • compositions 1 - 10 each containing an extract obtained by extraction with a water-containing organic solvent were prepared:
  • Composition 1 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 2 containing an extract obtained by extraction with a water containing organic solvent:
  • composition 3 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 4 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 5 containing an extract obtained by extraction with a water-containing organic solvent:
  • a mixture of 100 g of an extract from ginkgo leaves by extraction with a water-containing organic solvent and 200 ml of a 10 v/v % aqueous solution of gum arabic was subjected to fine disintegrating and coating with a surface modification apparatus for fine particle, to obtain a composition in powder form.
  • composition 6 containing an extract obtained by extraction with a water-containing organic solvent:
  • a mixture of the solution in water-containing ethanol prepared in (1) above (or emulsion made in (3) above) and 1.8 kg of lactose was granulated in a fluidized bed, whereby a composition in granules was obtained.
  • a suitable quantity of a lubricant By adding a suitable quantity of a lubricant, the granules could be made into tablets by the direct tableting method.
  • composition 7 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 1 The procedure of (1) above (Composition 1) was followed except for using 80 g of decaglycerin monolaurate in place of 100 g of gum arabic.
  • Composition 8 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 1 The procedure of (1) above (Composition 1) was followed except for using 80 g of gum arabic and 50 g of decaglycerin monooleate in place of 100 g of gum arabic.
  • compositions 1 - 5 were added 375 mg of lactose, and 5 mg of a fatty acid ester of sucrose as lubricant. Then, each mixture was tableted, whereby 400 mg of tablets was obtained respectively. As for Composition 6, it was tableted, without adding anything, to obtain 400 mg of tablets.
  • a dissolution test was performed, by the method and with the apparatus described in the Japanese Pharmacopoeia, for each lot of tablets obtained from Compositions 1 - 5, 7 and 8, and Comparison Example 1.
  • the paddle method was used, under the following conditions: Purified water 500 ml, 3 tab., wavelength ( ⁇ max) 266 nm, number of revolutions of spindle 100 rpm, and temperature of water 37 °C.
  • a double blind experiment was performed using tablets made from Compositions 1, 7 and 8 and tablets of Comparison Example 1, covering 128 patients with disturbance in cerebral circulation.
  • the tablets were given orally (before meal: 4 tablets at a time; 3 times/day).
  • Composition 9 containing an extract obtained by extraction with a water-containing organic solvent:
  • liquid extract solid content 15 % obtained from ginseng by extraction with a water-­containing ethanol with 25 v/v % alcohol content, was dissolved 10 g of gum arabic, and after that, the solvent in the solution was distilled off by the spray-­drying method, whereby a compound in powder form was obtained.
  • Composition 10 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 11 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 10 The procedure mentioned in (13) above (Composition 10) was followed except for using 10 g of the gum extracted from tamarind seeds in place of 15 g of the gum extracted from tamarind seeds, and adding 60 g of hexaglycerin monolaurate.
  • composition 12 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 13 containing an extract obtained by extraction with a water-containing organic solvent:
  • composition 12 The procedure mentioned in (16) above (Composition 12) was followed except for using 50 g of decaglycerin monostearate instead of 5 g of gum arabic.
  • the solvent in 100 g of Scopolia extract Japanese Pharmacopoeia, total alkaloids 1.0 %) was distilled off by the spray-drying method, whereby a powder product was obtained.
  • the powders of Compositions 10 - 13 each showed better dispersibility in water as compared with powders of Comparsion Examples 4 and 5.
  • the solid preparations such as tablets, granules and powder preparations; and non-­
  • alcoholic liquid preparations such as drinkable preparations and syrups, which are made from the compositions of this invention are well absorbed into the digestive tract and thus show a high bioavailability, although no alcohol is contained. Therefore, these preparations are most suitable for the treatment of disorder in cerebral circulation in the elderly people and minors, and also in patients with liver diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
EP89120283A 1988-11-04 1989-11-02 Composition contenant un extrait obtenu par extraction à l'aide d'un solvant organique aqueux et procédé de préparation à cet effet Expired - Lifetime EP0370284B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP279156/88 1988-11-04
JP27915688 1988-11-04
JP1261184A JP2818220B2 (ja) 1988-11-04 1989-10-05 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
JP261184/89 1989-10-05

Publications (3)

Publication Number Publication Date
EP0370284A2 true EP0370284A2 (fr) 1990-05-30
EP0370284A3 EP0370284A3 (en) 1990-12-12
EP0370284B1 EP0370284B1 (fr) 1993-05-26

Family

ID=26544960

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89120283A Expired - Lifetime EP0370284B1 (fr) 1988-11-04 1989-11-02 Composition contenant un extrait obtenu par extraction à l'aide d'un solvant organique aqueux et procédé de préparation à cet effet

Country Status (7)

Country Link
US (1) US5128131A (fr)
EP (1) EP0370284B1 (fr)
JP (1) JP2818220B2 (fr)
KR (1) KR960008289B1 (fr)
AU (1) AU620463B2 (fr)
CA (1) CA2002188A1 (fr)
DE (1) DE68906765T2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496705A1 (fr) * 1991-01-24 1992-07-29 Emil Flachsmann AG Composition spécialement apte pour être encapsulée dans une enveloppe solide et son procédé de préparation
WO1992021357A1 (fr) * 1991-06-07 1992-12-10 Krewel-Werke Gmbh Extraits de plantes secs et/ou concentres

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
JPH0724560B2 (ja) * 1990-06-01 1995-03-22 株式会社ヤクルト本社 植物体エキス含有飲料
JPH0734727B2 (ja) * 1991-09-05 1995-04-19 サンヨー食品株式会社 イチョウ葉抽出物入り清涼飲料
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
JP2656727B2 (ja) * 1994-05-17 1997-09-24 財団法人工業技術研究院 防湿性漢方顆粒製剤
JP3984288B2 (ja) * 1995-05-17 2007-10-03 秋山産業株式会社 青しょう子由来の予防・治療用組成物
US6171635B1 (en) 1997-05-06 2001-01-09 Iris G Zhao Coffee substitute
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6174531B1 (en) 1997-11-25 2001-01-16 Pharmanex Inc. Methods of preparation of bioginkgo
US6030621A (en) 1998-03-19 2000-02-29 De Long; Xie Ginkgo biloba composition, method to prepare the same and uses thereof
DK1660047T3 (en) 2003-08-13 2014-03-10 Biocon Ltd MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS
JP5766392B2 (ja) * 2008-06-19 2015-08-19 公立大学法人青森県立保健大学 ケルセチン生体吸収促進用組成物、および、ケルセチン生体吸収促進用飲食物
JP5546186B2 (ja) * 2009-09-14 2014-07-09 小川香料株式会社 植物エキス粉末の製造方法
JP6534275B2 (ja) * 2015-03-26 2019-06-26 横浜油脂工業株式会社 骨砕補エキス組成物
JP7027126B2 (ja) * 2017-11-02 2022-03-01 大塚食品株式会社 身体の冷え改善用の飲食品組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56118729A (en) * 1980-02-25 1981-09-17 Taiyo Koryo Kk Water-in-oil type emulsifier composition and water-in-oil type emulsion containing said composition
JPS5951214A (ja) * 1982-09-16 1984-03-24 Taiho Yakuhin Kogyo Kk バイオアベイラビリテイの高い薬剤の製造方法
GB2158839A (en) * 1984-05-15 1985-11-20 Oreal Anhydrous composition for cleansing the skin
JPS62106837A (ja) * 1984-12-03 1987-05-18 Takeda Chem Ind Ltd 乳化組成物
JPS62228246A (ja) * 1984-11-01 1987-10-07 Fuji Oil Co Ltd 凍結耐性を有するクリ−ム状油脂組成物の製造方法
JPS62265964A (ja) * 1986-05-14 1987-11-18 Nippon Oil & Fats Co Ltd 乳化液状ドレツシング
JPS63169931A (ja) * 1987-01-09 1988-07-13 Nippon Oil & Fats Co Ltd 低脂肪油中水型乳化油脂組成物
FR2613223A1 (fr) * 1987-04-03 1988-10-07 Biogalenique Laboratoires Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation
EP0360556A1 (fr) * 1988-09-20 1990-03-28 INDENA S.p.A. Extraits de Ginkgo biloba et leurs méthodes de préparation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US775249A (en) * 1904-02-27 1904-11-15 Ezekiel Mason Roberts Beverage.
US1631384A (en) * 1926-07-17 1927-06-07 Frostilla Company Lotion
US2008238A (en) * 1932-10-25 1935-07-16 Winthrop Chem Co Inc Liquid anthelmintics
DE2117429C3 (de) * 1971-04-08 1982-04-01 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Verfahren zur Herstellung eines Injektions- bzw. Infusionspräparates mit einem Gehalt an einem Wirkstoffgemisch aus den Blättern von Ginkgo biloba
DE3338995A1 (de) * 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Bilobalid enthaltende arzneimittel
JPS5791932A (en) * 1980-11-28 1982-06-08 Kuraray Co Ltd Polyprenyl compound
JPS5793914A (en) * 1980-12-03 1982-06-11 Rooto Seiyaku Kk Stabilizing method of scopolia root extract in pharmaceutical
US4501734A (en) * 1981-03-06 1985-02-26 Wakunaga Yakuhin Kabushiki Kaisha Promotion of absorption of drugs administered through the alimentary system
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
JPS6084227A (ja) * 1983-08-08 1985-05-13 Yoshihide Hagiwara 安定なハ−ブ植物水性抽出物及びその製法
JPS611617A (ja) * 1984-06-14 1986-01-07 Osaka Chem Lab ホルモン日内リズム調整食品
JPS6131039A (ja) * 1984-07-25 1986-02-13 Nippon Oil & Fats Co Ltd サスペンジヨンおよびその製造法
JPS61293922A (ja) * 1985-06-20 1986-12-24 Akio Fujikawa シミ改善料
JPH0764754B2 (ja) * 1984-10-02 1995-07-12 花王株式会社 経皮吸収促進剤及びこれを含有する皮膚外用剤
JPS61194031A (ja) * 1985-02-22 1986-08-28 Kanebo Ltd 制癌作用増強剤
JPS61271210A (ja) * 1985-05-28 1986-12-01 Pola Chem Ind Inc 化粧料
JPS6290167A (ja) * 1985-10-15 1987-04-24 松下電工株式会社 消臭剤
JPH01243945A (ja) * 1988-03-25 1989-09-28 Lotte Co Ltd 嫌煙ガム
JPH0231648A (ja) * 1988-07-21 1990-02-01 Daicel Chem Ind Ltd イチョウ抽出物入りチューインガム

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56118729A (en) * 1980-02-25 1981-09-17 Taiyo Koryo Kk Water-in-oil type emulsifier composition and water-in-oil type emulsion containing said composition
JPS5951214A (ja) * 1982-09-16 1984-03-24 Taiho Yakuhin Kogyo Kk バイオアベイラビリテイの高い薬剤の製造方法
GB2158839A (en) * 1984-05-15 1985-11-20 Oreal Anhydrous composition for cleansing the skin
JPS62228246A (ja) * 1984-11-01 1987-10-07 Fuji Oil Co Ltd 凍結耐性を有するクリ−ム状油脂組成物の製造方法
JPS62106837A (ja) * 1984-12-03 1987-05-18 Takeda Chem Ind Ltd 乳化組成物
JPS62265964A (ja) * 1986-05-14 1987-11-18 Nippon Oil & Fats Co Ltd 乳化液状ドレツシング
JPS63169931A (ja) * 1987-01-09 1988-07-13 Nippon Oil & Fats Co Ltd 低脂肪油中水型乳化油脂組成物
FR2613223A1 (fr) * 1987-04-03 1988-10-07 Biogalenique Laboratoires Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation
EP0360556A1 (fr) * 1988-09-20 1990-03-28 INDENA S.p.A. Extraits de Ginkgo biloba et leurs méthodes de préparation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 11, no. 317 (C-452)(2764) 15 October 1987, & JP-A-62 106837 (TAKEDA CHEM.) 18 May 1987, *
PATENT ABSTRACTS OF JAPAN vol. 12, no. 155 (C-494)(3002) 12 May 1988, & JP-A-62 265964 (NIPPON OIL) 18 November 1987, *
PATENT ABSTRACTS OF JAPAN vol. 12, no. 446 (C-546)(3293) 24 November 1988, & JP-A-63 169931 (NIPPON OIL) 13 July 1988, *
PATENT ABSTRACTS OF JAPAN vol. 12, no. 96 (C-484)(2943) 29 March 1988, & JP-A-62 228246 (FUJI OIL) 7 October 1987, *
PATENT ABSTRACTS OF JAPAN vol. 5, no. 195 (C-83)(867) 11 December 1981, & JP-A-56 118729 (TAIYOU KOURIYOU) 17 September 1981, *
PATENT ABSTRACTS OF JAPAN vol. 8, no. 145 (C-232)(1582) 6 July 1984, & JP-A-59 51214 (TAIHOU YAKUHIN KOGYO) 24 March 1984, *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496705A1 (fr) * 1991-01-24 1992-07-29 Emil Flachsmann AG Composition spécialement apte pour être encapsulée dans une enveloppe solide et son procédé de préparation
WO1992021357A1 (fr) * 1991-06-07 1992-12-10 Krewel-Werke Gmbh Extraits de plantes secs et/ou concentres

Also Published As

Publication number Publication date
US5128131A (en) 1992-07-07
CA2002188A1 (fr) 1990-05-04
JPH02223526A (ja) 1990-09-05
AU4439289A (en) 1990-05-10
EP0370284A3 (en) 1990-12-12
DE68906765T2 (de) 1993-09-02
EP0370284B1 (fr) 1993-05-26
KR900007432A (ko) 1990-06-01
KR960008289B1 (ko) 1996-06-24
DE68906765D1 (de) 1993-07-01
JP2818220B2 (ja) 1998-10-30
AU620463B2 (en) 1992-02-20

Similar Documents

Publication Publication Date Title
US5128131A (en) Process for preparing a watersoluble composition containing ginkgo leaf extracts
EP1210095B1 (fr) Composition de withania somnifera
JP2002523464A (ja) ピロリジジンアルカロイドを含まないペタサイトを含有する組成物
JP2003514761A (ja) イチョウ抽出物の調製法
EP1878445A1 (fr) Procede, formulation et utilisation de medicaments ou de nutriments avec une absorption orale amelioree
EP2320922B1 (fr) Association d'extraits de différentes plantes destinée à améliorer les symptômes des démences
JPH05502457A (ja) カバーカバ抽出物、これらの製造プロセスおよび使用
EP1499334B1 (fr) Fractions polaires sans petasines extraites de petasites et leur utilisation pour le traitement de la douleur
JP3293524B2 (ja) イチョウ葉抽出エキス担持粉体複合物及びその製造方法
CN114126594B (zh) 用于抑制TNF-α或IL-6产生的组合物
KR102293358B1 (ko) 사군자 초임계 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물
CN101108224A (zh) 一种植物生物碱提取物及其制剂与用途
JP2955679B2 (ja) エタノール代謝促進剤
CN109568519A (zh) 一种用于湿疹的中药组合物及其制备方法
WO2021106857A1 (fr) Composition prévenant ou atténuant l'angoisse liée à l'envie d'uriner, et composition pour amélioration du sommeil
EP0950411B1 (fr) Procédé pour la préparation d'un extrait d'écorce de Copalchi et l'utilisation des néoflavonoides pour le traitement des diabetes
EP0142036A1 (fr) Agent pharmaceutique contre les ulcères du tractus gastro-intestinal
JPH10330277A (ja) 漢方内服液剤
CN106866696B (zh) 三白草酮磺酸盐及其京尼平苷组合物在制备药物中应用
DE112006000924T5 (de) Neuartiges Verfahren zum Zubereiten von verarbeitetem Ginseng, um eine erhöhte Menge an Ginsenosid RG5 zu erhalten
KR100558930B1 (ko) 하르파고피툼프로쿰벤스및/또는하르파고피툼제이헤리덴스로부터얻은정제된추출물,이의제조방법및이의용도
CN111514197A (zh) 解酒组合物及其制备方法
US20230070032A1 (en) Solid cannabidiol compositions
WO2023242339A1 (fr) Composition comprenant de la pétasine et de l'isopétasine ayant un effet hépatoprotecteur
CN112011401A (zh) 一种具有润肠通便功效的保健山茶油及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): CH DE ES FR GB IT LI NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19901228

17Q First examination report despatched

Effective date: 19911216

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE ES FR GB IT LI NL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19930526

Ref country code: LI

Effective date: 19930526

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19930526

Ref country code: CH

Effective date: 19930526

ET Fr: translation filed
REF Corresponds to:

Ref document number: 68906765

Country of ref document: DE

Date of ref document: 19930701

ITF It: translation for a ep patent filed

Owner name: STUDIO TORTA SOCIETA' SEMPLICE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19971031

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19981102

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19981102

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990929

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19991125

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051102